Corcept Therapeutics

For more than 25 years, Corcept Therapeutics has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases. The company’s commercial portfolio includes treatments for hypercortisolism and oncology, having discovered over 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. With advanced clinical trials in patients with hypercortisolism, solid tumors, ALS, and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today.